Hemorrhagic complications after intravitreal ranibizumab injection for polypoidal choroidal vasculopathy

Canadian Journal of Ophthalmology

Volumn 47, Issue 2, 2012, Pages 170-175

  Cho, Han Joo ^a   Lee, Dong Won ^a   Cho, Sung Won ^a   Kim, Chul Gu ^a   Kim, Jong Woo ^a  

^a Konyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CILIARY DISK; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; ENDOPHTHALMITIS; EYE INJURY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POLYPOIDAL CHOROIDAL VASCULOPATHY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; RETINA DETACHMENT; RETINA HEMORRHAGE; RISK FACTOR; SYSTEMIC DISEASE; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 84862817832     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.01.005     Document Type: Article

References (23)

1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1-8. (Pubitemid 20201879)
2. Yannuzzi LA, Ciardella A, Spaide RF, et al. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997;115:478-85. (Pubitemid 27172703)
3. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392-6. (Pubitemid 37243739)
4. Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100-10.
5. Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: One-year results of a prospective case series. Ophthalmology. 2004; 111:1576-84. (Pubitemid 39030815)
6. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmololgy. 2008;115:141-6. (Pubitemid 350309415)
7. Akaza E, Yuzawa M, Matsumoto Y, et al. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2007;51:270-7. (Pubitemid 47174610)
8. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008; 92:70-3.
9. Lai TY, Chan WM, Liu DT, et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92:661-6. (Pubitemid 351684177)
10. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2009;148;70-8.
11. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141:456-62. (Pubitemid 43265948)
12. Matsuoka M, Ogata N, Otsuji T, et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol. 2004;88:809-15. (Pubitemid 38725593)
13. Lantry LE. Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications. Curr Opin Mol Ther. 2007;9:592-602. (Pubitemid 350179099)
14. Gomi F, Tano Y. Polypoidal choroidal vasculopathy and treatments. Curr Opin Ophthalmol. 2008;19:208-12. (Pubitemid 351535916)
15. Hirami Y, Tsujikawa A, Otani A, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2007;27:335-41. (Pubitemid 46398898)
16. Ojima Y, Tsujikawa A, Otani A, et al. Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2006;141:958-60.
17. Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol. 2008;92:210-2. (Pubitemid 351224096)
18. Krishnan R, Goverdhan S, Lochhead J. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. Clin Exp Ophthalmol. 2009;37:384-8.
19. Kiss C, Michels S, Prager F, et al. Retinal pigment epithelium tears following intravitreal ranibizumab therapy. Acta Ophthalmol Scand. 2007;85:902-3. (Pubitemid 350142817)
20. Garg S, Brod R, Kim D, et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Exp Ophthalmol. 2008;36:252-6. (Pubitemid 351560274)
21. Bakri SJ, Kitzmann AS. Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol. 2007;143:505-7. (Pubitemid 46273349)
22. Cackett P, Htoon H, Wong D, Yeo I. Haemorrhagic pigment epithelial detachment as a predictive feature of polypoidal choroidal asculopathy in a Chinese population. Eye. 2009;24:789-92.
23. Kuhli-Hattenbach C, Fischer IB, Schalnus R, Hattenbach LO. Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy. Am J Ophthalmol. 2010;149:316-21.